Announcements Trials
Browse Landscape

Phase

Phase 4 4Phase NA 2Phase 2 2Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 5Other hematologic neoplasm 4Lymphoid 4Plasma cell 3Myeloid 3Breast 3Sarcoma 2Gynecologic 2Genitourinary 2CNS 2Gastrointestinal 1Classical hematology 1

Conditions

Anemia 64Neoplasms 38Venous Thromboembolism 29Leukemia 21Anemia, Refractory, with Excess of Blasts 20Myelodysplastic Syndromes 19Lymphoma 14Thrombocytopenia 13Multiple Myeloma 12Leukemia, Myelomonocytic, Chronic 12Venous Thrombosis 11Pulmonary Embolism 11Febrile Neutropenia 11Breast Neoplasms 10Myeloproliferative Disorders 9Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 9Neoplasms, Plasma Cell 8Lymphoma, Follicular 8Leukemia, Myeloid, Acute 8Primary Myelofibrosis 6Neutropenia 6Hodgkin Disease 6Hemophilia A 6Lung Neoplasms 5Anemia, Refractory 5Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Precancerous Conditions 4Lymphoproliferative Disorders 4

Interventions

pegfilgrastim 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Fever × Classical hematology × Clear all
NCT00911170 2017-12-29

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Amgen

Phase 3 Completed
847 enrolled 21 charts
Classical hematologyGastrointestinal

Colonic Neoplasms, Fever, Neoplasms, Neutropenia, Rectal Neoplasms, Colorectal Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡